Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company
Clinical-Stage Biotechnology Company Is Preparing a Phase 2a Trial of Nu-3, a Topical Bisphosphocin® Gel, in Infected Diabetic Foot Ulcers B2i Digital Campaign to Center on Nu-3, the Upcoming Phase 2a Trial, and the Bisphosphocin® Class Behind It NEW YORK, NY - August 25, 2026 ( NEWMEDIAWIRE ) - B2i Digital, Inc. today welcomed Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) as its newest Featured Company. The Sarasota, Florida clinical-stage biotechnology company develops the Bisphosphocin® class, a novel group of fast-acting, broad-spectrum antimicrobials for infectious diseases and antibiotic-resistant bacterial strains, and B2i Digital will bring that work, and the clinical program built around it, to its network of retail and institutional market participants. A full company profile is coming soon to https://b2idigital.com/featured-companies . “Antimicrobial resistance keeps narrowing the list of drugs that still work against all pathogens, and the compounds coming to replace them are mostly variations on mechanisms that bacteria have already learned to defeat,” said David Shapiro, Chief Executive Officer of B2i Digital, Inc. “Lakewood-Amedex has spent years on a compound
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes
